C.J. Bol
Impact in
- Oncology top 10%
- Drug Transport and Resistance Mechanisms
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 5
- Drug Transport and Resistance Mechanisms 3
- Cancer-related Molecular Pathways 2
- HER2/EGFR in Cancer Research 1
- Co-authors
- Peter Palmer (5 shared papers)R. Woestenborghs (2 shared papers)Alex Sparreboom (2 shared papers)Lia van Zuylen (2 shared papers)Ate van der Gaast (2 shared papers)Jaap Verweij (2 shared papers)Ronald E. Gress (1 shared paper)David Köhler (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)European Journal of Cancer (2 papers)Anti-Cancer Drugs (1 paper)American Heart Journal (1 paper)Journal of Interventional Cardiology (1 paper)
- Partner nations
- NetherlandsBelgiumUnited States
In The Last Decade
C.J. Bol
9 papers receiving 540 citations
Peers
Comparison fields: 5 of 54
- Oncology 303
- Hematology 46
- Molecular Biology 240
- Genetics 31
- Pharmacology 24
Countries citing papers authored by C.J. Bol
This map shows the geographic impact of C.J. Bol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.J. Bol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.J. Bol more than expected).
Fields of papers citing papers by C.J. Bol
This network shows the impact of papers produced by C.J. Bol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.J. Bol. The network helps show where C.J. Bol may publish in the future.
Co-authors
The 25 scholars most cited alongside C.J. Bol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 217 | |
| 2 | 2002 | 111 | |
| 3 | The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. | 2000 | 83 |
| 4 | 2001 | 56 | |
| 5 | 2002 | 54 | |
| 6 | 2008 | 17 | |
| 7 | 2009 | 11 | |
| 8 | 2002 | 8 | |
| 9 | 1999 | 1 | |
| 10 | 1987 | 0 |
About C.J. Bol
C.J. Bol is a scholar working on Oncology, Molecular Biology, Pharmacology, Surgery and Pediatrics, Perinatology and Child Health, having authored 10 papers that have together received 558 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (3 papers), Pharmacogenetics and Drug Metabolism (2 papers), Pharmacological Effects and Toxicity Studies (2 papers), Coronary Interventions and Diagnostics (2 papers), Cancer-related Molecular Pathways (2 papers), Neuroblastoma Research and Treatments (1 paper), HER2/EGFR in Cancer Research (1 paper) and Berberine and alkaloids research (1 paper). The work is most often cited by research in Oncology (303 citations), Hematology (46 citations), Molecular Biology (240 citations), Genetics (31 citations) and Pharmacology (24 citations). C.J. Bol has collaborated with scholars based in Netherlands, Belgium and United States. Frequent co-authors include Peter Palmer, R. Woestenborghs, Alex Sparreboom, Lia van Zuylen, Ate van der Gaast, Jaap Verweij, Ronald E. Gress, David Köhler, Judy H. Chiao and G. Larkin. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Anti-Cancer Drugs, American Heart Journal and Journal of Interventional Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.